Quantum BioPharma $QNTM: Lucid-MS, unbuzzd™ & 2026 Milestones | BioMedWire Podcast

Quantum BioPharma is developing a drug candidate called Lucid-MS to reverse the loss of mobility caused by multiple sclerosis. This condition currently lacks effective direct treatment, and nearly 3 million people suffer from it globally. The company is actively pursuing a phase 2 trial, marking the first time the drug will be tested in individuals with MS. This development has already shown promising results in prior in-vivo animal models demonstrating improved mobility. Additional product assets include unbuzzd, a commercially available product formulated to accelerate the rate of blood alcohol metabolism. The company also addresses broader corporate governance through active legal strategies against stock manipulation, aiming to protect shareholder interests from market abuses.